AtriCure CEO resigns in spite of positive Q2 results
This article was originally published in Clinica
Executive Summary
David Drachman has resigned as CEO and president of cardiac ablation specialist AtriCure, in spite of the firm posting top-line growth during its second fiscal quarter. Mr Drachman has already left the firm's board of directors, but will continue to serve the company until 30 September. He told Clinica he was "in the process of evaluating new medical device opportunities", but would not give further details. AtriCure's chairman Richard Johnston will assume Mr Drachman's responsibilities, under the firm's newly-formed Office of the Chairman, while the firm searches for a new CEO. Michael Hooven, one of AtriCure's founders, a current board member, and CEO and president of the company from 2000-2002, has also joined the Office of the Chairman. The West Chester, Ohio company reported Q2 sales of $18.3m, up 9% year-on-year. However, the firm's net loss widened to $1.3m, versus $0.9m during the same period last year. Last year, AtriCure's Synergy ablation system has received premarket approval (PMA) from the US FDA for the treatment of atrial fibrillation (AF), making it the first device of its kind to be approved in the US specifically for this indication (www.clinica.co.uk, 20 December 2011).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.